Yikolai Bio Raises Over RMB 100 Million in New Round Led by Huatai Zijin

On April 3, 2019, VCBeat learned that Shanghai Abiochem Biopharmaceutical Technology Co., Ltd. had completed a new round of financing exceeding RMB 100 million. This round was led by Huatai Zijin, with participation from Binghong Capital, Yida Capital, and existing shareholder Honghui Capital.

Abiochem Biotechnology is a high-tech enterprise with leading enzyme engineering and synthetic biology technologies. The company focuses on the research, development, and scaled production of biocatalysis and synthetic biology solutions. Currently, Abiochem’s biosynthesis technologies have been successfully applied in pharmaceuticals, health supplements, agrochemicals, and other fields, as it strives to become an internationally leading bio-manufacturing company.

Luo Yu, founder of Abiochem Biotechnology, stated, “We extend our gratitude to both new and existing investors for their recognition and support of the company. Abiochem will continue to promote the application of biotechnology in chemical manufacturing, leveraging capital to achieve leapfrog growth and repay society with greener and more efficient products.” According to VCBeat, the funds from this financing round will be primarily used to expand the company’s R&D platform and increase production capacity at its Taizhou manufacturing base.

Ms. Cao Qun, General Manager of Huatai Zijin, stated, “Abiochem has successfully applied innovative biocatalysis technologies to industrial production, driving the transition from traditional chemical synthesis to more efficient and eco-friendly biosynthesis, thereby achieving a significant leap in productivity. We are honored to support a team like Abiochem’s, which combines scientific expertise with entrepreneurial spirit. We look forward to seeing them commercialize more research achievements and achieve even more remarkable breakthroughs in the field of synthetic biology in the near future.”

Huatai Zijin is the private equity fund subsidiary of Huatai Securities (601688), specializing in private equity investment. Leveraging the full business chain advantages of Huatai Securities and adhering to the investment philosophy of “growing together with entrepreneurs,” it provides comprehensive capital services to partners by drawing on its abundant financial and industrial resources.

The company has a registered capital of RMB 6 billion and assets under management exceeding RMB 40 billion, with a portfolio of funds spanning private equity (PE), mergers and acquisitions (M&A), funds of funds (FOF), and industrial sectors. Adhering to its industry positioning, Huatai Zijin builds on robust industry research to deeply cultivate strategic emerging industries such as healthcare and TMT, accumulating extensive industry experience and resources. Its healthcare investment portfolio includes Mindray Medical (300760), Getein Biotech (603387), WuXi AppTec (603259), BrightGene Bio-medical Technology, RemeGen, Aidi Pharmaceutical, Geneseeq, Shuoshi Biotech, Shandong Shuyu Pharmacy, Yimeier, and Happy Dental. Leveraging the capital operation advantages of its securities firm ecosystem, the company has facilitated the successful listing of numerous enterprises on China’s A-share market and provided comprehensive support to industry leaders, establishing leading capabilities in industrial investment and M&A within the sector.

Binghong Capital is a leading professional equity investment firm in China. Managing over ten funds with assets under management nearing RMB 4 billion, Binghong Capital focuses on healthcare, energy conservation and environmental protection, high-end manufacturing, and consumption upgrading, with investment activities spanning across China. To date, Binghong Capital has invested in nearly 80 companies, with approximately 30 portfolio companies successfully listed or quoted on stock exchanges. Notable healthcare investments include Meinian Onehealth Healthcare (002044), Pert Medical (835879), Eproncon (835852), Geneseeq, Chengdu Xichan, and Auscan Biologics.

Jiangsu Yida Equity Investment Fund Management Co., Ltd. (hereinafter referred to as “Yida Capital”) was established in 2014 through the internal mixed-ownership reform of Jiangsu High-Tech Investment Group, a well-established and renowned state-owned venture capital firm. It is currently one of the most influential venture capital institutions in China, boasting the strongest industry research capabilities, the largest asset under management scale, and the highest level of investment specialization.

As of the end of February 2019, the management team of Yida Capital had established a total of 89 equity investment funds with various strategic focuses, managing assets under management (AUM) of RMB 96.9 billion. It has cumulatively invested in and supported more than 750 startups, helping 161 of them list on domestic and international capital markets.

Hui Capital is a leading investment platform in China’s healthcare industry. Hui Capital manages dual-currency funds in both US dollars and Renminbi, with total assets under management approaching RMB 10 billion.

Portfolio includes: Mindray Medical (300760), Pharmaron (300759), Yuwell Medical (002223), WuXi AppTec (603259), Linhua Medical (835637), STA Pharmaceutical (832159), Kintor Pharmaceutical, Borui Biology, Baiyang Pharmaceutical, Sansure Biotech, JetMed Medical, Kangtuo Medical, Malo Clinic, Little White Rabbit Dental, Dr. Cui Yutao Children's Health Management Center, Petshin and other high-quality enterprises.

Honghui Capital upholds the spirit of “professionalism, prudence, and innovation,” committing itself to serving entrepreneurs and founders in the health industry, and jointly building an industrial investment platform shared by all entrepreneurs and investors in the healthcare sector.